Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Catz

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Annals of Neurology|March 1, 1988
Cerebrospinal fluid antibodies to myelin basic protein in acute idiopathic optic neuritisK G Warren, I Catz, C Bauer
Journal of the Neurological Sciences|December 12, 1997
Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosisK G Warren, I Catz, K W Wucherpfennig
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 1, 1983
CSF myelin basic protein levels in acute optic neuritis and multiple sclerosisK G Warren, I Catz, T A McPherson
Annals of Neurology|March 1, 1994
Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosisK G Warren, I Catz, E Johnson, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|February 1, 1986
Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbationsK G Warren, I Catz, V M Jeffrey, et al.
European Journal of Neurology|August 2, 2006
Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatmentK G Warren, I Catz, L Z Ferenczi, et al.
The Journal of Clinical Investigation|September 1, 1997
Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopesK W Wucherpfennig, I Catz, S Hausmann, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 1, 1983
Myelin basic protein: a component of circulating immune complexes in multiple sclerosisM K Dasgupta, I Catz, K G Warren, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 29, 2014
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesisS N Reinke, D L Broadhurst, B D Sykes, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Annals of Neurology|March 1, 1988
Cerebrospinal fluid antibodies to myelin basic protein in acute idiopathic optic neuritisK G Warren, I Catz, C Bauer
Journal of the Neurological Sciences|December 12, 1997
Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosisK G Warren, I Catz, K W Wucherpfennig
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 1, 1983
CSF myelin basic protein levels in acute optic neuritis and multiple sclerosisK G Warren, I Catz, T A McPherson
Annals of Neurology|March 1, 1994
Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosisK G Warren, I Catz, E Johnson, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|February 1, 1986
Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbationsK G Warren, I Catz, V M Jeffrey, et al.
European Journal of Neurology|August 2, 2006
Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatmentK G Warren, I Catz, L Z Ferenczi, et al.
The Journal of Clinical Investigation|September 1, 1997
Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopesK W Wucherpfennig, I Catz, S Hausmann, et al.
The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques|November 1, 1983
Myelin basic protein: a component of circulating immune complexes in multiple sclerosisM K Dasgupta, I Catz, K G Warren, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 29, 2014
Metabolomic profiling in multiple sclerosis: insights into biomarkers and pathogenesisS N Reinke, D L Broadhurst, B D Sykes, et al.
Pageof 3